Davita Inc vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Davita Inc trades at $183.41 (market cap $11.53B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $283.97 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is far larger — about 4.2× Davita Inc's market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| DVA | WAB | |
|---|---|---|
Market Cap | $11.53B | $48.39B |
Volume | 444,368 | 801,560 |
Sector | Health | Industrials |
52-Week High | $240.96 | $305.79 |
52-Week Low | $103.87 | $193.43 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.25B | $54.29B |
Dividend Yield | — | 0.43% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $182.08, up 0.17% with a bullish technical signal and strong institutional backing. The stock shows consistent earnings beats with Q2 2026 EPS of $4.02 exceeding expectations. Revenue growth has been steady from $11.6B in 2022 to $13.64B in 2025, though net margins fluctuated. Recent partnership expansion with Humana for value-based kidney care demonstrates strategic growth initiatives. The stock trades at reasonable valuations with P/E of 15.31 and P/S of 0.9, while maintaining strong profitability metrics including 635.3% ROE.
DVA presents a compelling investment case with analyst consensus price target of $235.67 offering 29% upside potential. The company benefits from demographic tailwinds in healthcare services and Warren Buffett's significant ownership. However, investors face risks from regulatory pressures, debt levels at 65.55% of assets, and margin compression concerns highlighted in recent earnings. The stock's technical position near key support at $181 requires monitoring for sustained bullish momentum.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →